Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
Abstract
Amyloid, Tau, and neurodegeneration biomarkers can stage Alzheimer's Disease (AD). Synaptic biomarkers may help track cognition.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2019
- Source ID
- 10.1016/j.trci.2019.11.002
Entities
People
- David P. Salmon
- Denis Smirnov
- Desheng Xu
- Dirk Jacobs
- Douglas Galasko
- Eugeen Vanmechelen
- Hugo Vanderstichele
- Jeroen Vanbrabant
- Meifang Xiao
- Nele Dewit
- Paul Worley
- The Alzheimer's Disease Neuroimaging Initiative (adni)
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Chiron Corporation
- Eli Lilly and Company
- Flemish Enterprise Agency
- Foundation for the National Institutes of Health
- GE HealthCare
- Hoffmann-La Roche
- Johns Hopkins University
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of California, San Diego